Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Osteoporosis, Postmenopausal: later-stage trial registry
2 of 15 indexed Osteoporosis, Postmenopausal trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 2 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Osteoporosis, Postmenopausal: 15 US clinical trials tracked, 2 recruiting.
Osteoporosis, Postmenopausal is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 10 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 5 of these trials.
Enrollment posture brief
Registry condition osteoporosis-postmenopausal
OPEN 2 | RECR 13% | LATE 10 | EARLY 3 | RANK #1140 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Drug Addiction (13% recruiting · 15 trials)
Osteoporosis, Postmenopausal lists 2 open slots (13% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Osteoporosis, Postmenopausal on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Osteoporosis, Postmenopausal is recruiting below its size-band peers.
2 of 15 indexed trials (13.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Osteoporosis, Postmenopausal research.
Eli Lilly and Company accounts for 5 of 15 trials (33.3%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Osteoporosis, Postmenopausal trials plan to enrol fewer than 100 people.
Median target enrolment is 70 among the 13 trials that report a genuine target (sentinel values excluded). 8 of those (61.5%) plan for fewer than 100 participants.
-
Osteoporosis, Postmenopausal research is mostly interventional.
14 interventional and 1 observational studies make up this index (93.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Combined Anabolic Therapy
Massachusetts General Hospital
NCT06558188
Mechanisms of Anabolic Osteoporosis Therapy
Massachusetts General Hospital
NCT05688969
Comparative Efficacy, Safety, PK, and Immunogenicity Study
Luye Pharma Group
NCT05853354
Romosozumab Use to Build Skeletal Integrity
Susan L. Greenspan
NCT05058976
Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone
Hospital for Special Surgery, New York
NCT04467983
Comparative Antiresorptive Efficacy Discontinuation of Denosumab
Massachusetts General Hospital
NCT03623633
Patient- and Physician-Based Osteoporosis Education
Brigham and Women's Hospital
NCT00073190
Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
Eli Lilly and Company
NCT00670501
Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene or Placebo
Eli Lilly and Company
NCT00532246
Circulating miRNA in Primary Hyperparathyroidism
University of Pennsylvania
NCT03931109
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
Eli Lilly and Company
NCT00927186
3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women
University of Pittsburgh
NCT00222872
A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
Eli Lilly and Company
NCT00557310
Effects of Black Cohosh on Menopausal Hot Flashes
National Center for Complementary and Integrative Health (NCCIH)
NCT00010712
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
Eli Lilly and Company
NCT00046137
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 3 |
| Phase 4 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Osteoporosis, Postmenopausal records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Osteoporosis, Postmenopausal trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Osteoporosis, Postmenopausal page
15 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Osteoporosis, Postmenopausal trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Eli Lilly and Company sponsors the most Osteoporosis, Postmenopausal trials on record, review their full trial history before evaluating a specific study. See Eli Lilly and Company's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Osteoporosis, Postmenopausal condition card totals 15 registered trials; most-linked intervention Placebo; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.